What is Mesoblast Ltd (MESO) stock price today?

Mesoblast Ltd (MESO) currently trades at $14.74 per share. The stock has a market capitalization of $1.91B and a P/E ratio of —x.

Is MESO stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Mesoblast Ltd has a Smart Value Score of 25/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Mesoblast Ltd's revenue and earnings?

Mesoblast Ltd has trailing twelve-month (TTM) revenue of $65.38M with profit margins of -144.30%. Earnings per share (EPS) is $-0.70.

Is MESO stock overvalued or undervalued?

Based on our DCF model, Mesoblast Ltd's intrinsic value is $33.69, representing a margin of safety of 45.68%. The stock currently trades at a P/E of —x.

MESO

Mesoblast Ltd

NASDAQ: MESO · HEALTHCARE · BIOTECHNOLOGY

$14.74

-0.41% today

Updated 2026-05-08

Market cap

$1.91B

P/E ratio

—

P/S ratio

29.26x

EPS (TTM)

$-0.70

Dividend yield

—

52W range

$10 – $22

Volume

0.3M

Market cap

$1.91B

P/E ratio

—

P/S ratio

29.26x

EPS (TTM)

$-0.70

Dividend yield

—

52W range

$10 – $22

Volume

0.3M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

7.3

Growth

B+

5.0

Quality

C+

2.0

Profitability

6.7

Valuation

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →195 stocks currently score above 75

Price targets

Analyst target

$35.00

+137.45%

12-Month target

—

Intrinsic (DCF)

$33.69

Margin of safety

+45.68%

2 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Revenue growth 1,527.00% QoQ

+ 45.68% below intrinsic value

Risks

- Thin margins at -144.30%

- Negative free cash flow $-4.46M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$10.21M	$7.50M	$5.90M	$17.20M	$65.38M
Net income	$-91.35M	$-81.89M	$-87.96M	$-102.14M	$-27.10M
EPS	—	—	—	—	$-0.70
Free cash flow	$-66.01M	$-63.58M	$-48.79M	$-50.68M	$-4.46M
Profit margin	-894.59%	-1,091.71%	-1,490.27%	-593.92%	-144.30%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
MESO	$1.91B	25	7.3	2.0	6.7	5.0	+45.68%	Avoid
LLY	$869.41B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$535.63B	59	4.7	9.0	3.3	6.0	-38.45%	Buy
ABBV	$358.55B	63	4.0	8.0	4.0	5.0	-20.52%	Buy
UNH	$335.78B	54	5.3	5.5	7.3	4.8	+42.20%	Buy
AZN	$286.68B	62	6.0	8.5	5.3	5.0	+6.60%	Buy

Smart narrative

Mesoblast Ltd trades at $14.74. Our Smart Value Score of 25/100 indicates the stock is weak. TTM revenue stands at $65.38M. with profit margins at -144.30%. Our DCF model estimates intrinsic value at $33.69.

Frequently asked questions

What is Mesoblast Ltd's stock price?

Mesoblast Ltd (MESO) trades at $14.74.

Is Mesoblast Ltd overvalued?

Smart Value Score 25/100 (Grade F, Strong Sell). DCF value $33.69.

What is the price target of Mesoblast Ltd (MESO)?

The analyst target price is $35.00, representing +137.4% upside from the current price of $14.74.

What is the intrinsic value of Mesoblast Ltd (MESO)?

Based on our DCF model, intrinsic value is $33.69, a +45.7% margin of safety versus $14.74.

What is Mesoblast Ltd's revenue?

TTM revenue is $65.38M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio29.26x

ROE-18.20%

Beta0.79

50D MA$15.20

200D MA$16.37

Shares out0.13B

Float0.82B

Short ratio—

Avg volume0.3M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

MESO vs LLY →MESO vs JNJ →MESO vs ABBV →Stock screener →